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Renal disease is associated with increased CVD events. The Trial to Assess Chelation Therapy (TACT) showed chelation (Chel) reduced CVD outcomes. 
We evaluated whether the effect of Chel differed depending on renal function.
TACT randomized patients (pts) with prior MI and Cr <2.0 mg/dl to Chel or placebo (PL) infusions. The primary outcome included death, reinfarction, 
CVA, CABG/PCI or angina hospitalization. Pts were grouped by renal function, CKD 1 (eGFR > 90), 2 (eGFR 60-89), and 3 (eGFR <60 ml/min), and 
compared using Cox proportional hazards model. Cumulative event rates were calculated using the Kaplan-Meier method.
Among the 1708 pts (CKD 1 n=250, CKD 2 n= 1003, CKD 3 n=453) CKD 3 pts were older and more had a history of CHF, PVD, hypertension, 
diabetes and CABG versus CKD 1 and 2 pts (all Pearson χ-square p<0.001). The primary outcome occurred in 23% CKD 1, 27% CKD 2 and 34% 
CKD 3 pts (p=0.0193). The HR [95% CI] for the primary outcome for Chel versus PL was 1.17 [.0.69, 1.99] in CKD 1, 0.78 [0.62, 1.00] in CKD 2 and 
0.83 [0.60, 1.15] in CKD 3 (see Fig). The interaction between CKD group and treatment was not significant (p=0.384).
Despite excluding pts with severe renal disease, a higher percentage of CKD 3 pts experienced the primary outcome. The effect of Chel varied across 
CKD groups, but no significant interaction by CKD group was found. Although the CKD 3 group is relatively small, the point estimate of the effect of 
Chel in pts with moderately impaired renal function is consistent with the overall positive results of TACT.
 
